Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy

ConclusionsER+/HER2 − patients most likely to benefit from NAC are those with PR− and HP tumors. Patients with ILC are unlikely to downstage in the breast or axilla compared with IDC. The use of these criteria can assist in defining the initial treatment approach.

http://link.springer.com/10.1245/s10434-017-5898-z

Source: Annals of Surgical Oncology - August 1, 2017 Category: Cancer & Oncology Source Type: research